What the appointment actually involves

A ChondroFiller™ appointment is an outpatient clinic visit — there is no theatre, no incision, and no general anaesthetic involved. Patients arrive, receive the injection, and leave the same day.

The appointment follows a clear sequence. Before the needle is placed, the clinician reviews any existing imaging to confirm the nature and location of the cartilage defect. The target joint is then positioned, the skin is cleaned, and a local anaesthetic is used to numb the area. From that point, real-time ultrasound imaging guides the entire injection: the probe identifies the precise entry point and tracks the needle continuously as the collagen gel is delivered into the defect. Once in place, the gel stabilises naturally within a few minutes — no fixatives or stitches are needed.

The procedure is low-intensity by design, but the level of precision involved should not be underestimated. Ultrasound guidance is used throughout specifically because accurate placement within a focal defect matters; this is not a straightforward injection into a large joint space. The whole appointment — from preparation to in-clinic observation — typically fits within a single morning or afternoon slot.

Who this injection pathway is designed for

Suitable candidates share one defining characteristic: a localised, focal cartilage defect confirmed on MRI. That imaging step is a prerequisite for booking — it allows the clinician to map the defect's position and characteristics and to rule out the widespread joint degeneration that the injection pathway is not designed to address.

In terms of joint coverage, the injection route is broadly applicable. Evidence supports its use across at least eight joint types, including the knee, hip, shoulder, ankle, elbow, foot, hand, and wrist. The injection pathway also carries no published upper age limit and no defect-size ceiling specific to this route — distinctions that set it apart from some other cartilage interventions.

Not everyone with a focal defect will be suitable. Contraindications include an active infection in the target joint, systemic inflammatory arthritis, immunosuppressive therapy, and poorly controlled diabetes. Patients who are unlikely to follow post-injection guidance or who hold expectations of guaranteed or immediate pain relief are also considered unsuitable at the assessment stage.

Where imaging or clinical findings suggest that direct injection is insufficient, an arthroscopic surgical alternative exists. Critically, both routes deliver the same collagen scaffold and share the same biological mechanism of repair — what differs is procedure intensity, not what happens inside the joint afterwards. A specialist assessment following MRI review determines which pathway is appropriate for any given patient.

The procedure sequence, stage by stage

Stage 1 — Preparation. Before the patient is positioned, the acellular collagen liquid is warmed to 37°C in line with manufacturer instructions. This step is easy to overlook in patient-facing descriptions, but it matters: body-temperature delivery supports the in-situ gelling behaviour that makes the scaffold stable once it reaches the defect.

Stage 2 — Positioning and sterile field. The patient is settled comfortably for the target joint — the exact position varies depending on whether the knee, hip, shoulder, or another joint is being treated. The skin over the injection site is thoroughly cleaned and sterilised, then a local anaesthetic is administered to the skin and the soft tissue layer overlying the joint capsule, minimising discomfort during needle insertion.

Stage 3 — Ultrasound localisation. The clinician applies an ultrasound probe to the joint and scans in real time to confirm the precise needle entry point and verify the position of the cartilage lesion. This imaging step determines exactly where the needle will be placed before any injection begins — accuracy at this stage is directly relevant to how well the collagen reaches the target cavity.

Stage 4 — Injection. The pre-warmed collagen liquid is delivered from a specialised dual-chamber syringe. The needle is advanced under continuous ultrasound visualisation, and the gel is introduced slowly to fill the defect cavity. No healthy surrounding tissue is removed or disturbed during this stage.

Stage 5 — In-situ gelling. Once deposited, the scaffold self-gels at body temperature in approximately 3–5 minutes. No adhesive, curing agent, or suture is required to hold it in place. The patient remains still briefly while the material stabilises, after which the appointment concludes.

Why real-time ultrasound guidance is non-negotiable

Precise placement is not a preference for a product like this — it is a functional requirement. ChondroFiller™ is a high-viscosity collagen gel designed to fill a focal defect cavity and self-gel in position; if the needle tip is even partially outside that cavity, the scaffold cannot perform its intended role. Landmark-guided injection — estimating needle position from surface anatomy alone — cannot reliably guarantee that precision.

The published evidence on guidance technique reinforces this. A 2025 Level I systematic review found ultrasound-guided intra-articular knee injections achieved 95.4% accuracy, compared with 82.0% for landmark-guided approaches, with nearly all included studies showing improved outcomes in the ultrasound group. A 2026 prospective observational study sharpened that picture further: more than one in four landmark-guided injections — 27.2% — were confirmed as extra-articular or suboptimally placed on arthroscopic assessment, with accuracy deteriorating further in patients with a BMI of 30 or above.

These are general injection-accuracy data rather than ChondroFiller-specific trial figures, but they directly illustrate the stakes. For a corticosteroid or viscosupplement, an imprecise placement may still deliver partial symptomatic benefit. For a scaffold that must mechanically fill a mapped defect cavity, the gel reaching somewhere other than the repair site defeats the purpose of the treatment.

Real-time imaging allows the clinician to observe needle position and gel distribution as the injection proceeds, adjusting before the deposit is complete — a level of intra-procedural control that surface anatomy alone cannot provide. For this reason, ultrasound guidance is a clinical standard for scaffold-based injection treatment, not an optional upgrade.

What the collagen scaffold does once it's in place

ChondroFiller™ contains no donor cells, stem cells, or biological additives of any kind. It is an acellular Type I collagen hydrogel — a three-dimensional matrix — and its job is to provide a structural framework that the body can move into, rather than to deliver repair capacity directly.

Once the scaffold is in place, progenitor cells from two local sources — the synovium lining the joint and the subchondral bone beneath the defect — begin migrating into the collagen matrix. Over time, these cells populate the scaffold and lay down repair tissue, while the collagen matrix itself is gradually resorbed. Think of it as a scaffolding frame erected at a repair site: the frame organises the work, then slowly comes down as the new structure takes shape.

Crucially, this repair biology is the same regardless of how the scaffold reaches the defect. Whether ChondroFiller is placed via an outpatient injection or delivered during an arthroscopic procedure, the cellular events that follow are identical. The two pathways differ in procedural intensity — one requires a theatre, a general anaesthetic, and a longer recovery; the other does not — but not in what happens at the defect site afterwards. For patients who are suitable candidates for the injection route, this equivalence of mechanism is clinically meaningful.

Evidence supports a regenerative repair process, and the scaffold is designed to facilitate it. What that repair tissue looks and functions like over the longer term — and how it compares with native hyaline cartilage — is an area where published data remain limited; product-specific randomised trial outcomes are not yet available. Patients should approach ChondroFiller as a biologically active repair scaffold, not a guaranteed cartilage replacement.

Injection versus the surgical alternative — what actually differs

Pathway selection between the injection route and arthroscopic implantation is not a question of efficacy — it is a question of procedural suitability. The same scaffold performs the same repair function in either setting; what changes is the surrounding clinical burden and whether the patient's anatomy and health status make one route more appropriate than the other.

The arthroscopic route requires a general anaesthetic and a theatre environment with a longer associated recovery. That difference matters when a patient has comorbidities that increase anaesthetic risk, when prior joint surgery has altered the internal anatomy, or when minimising procedural burden is itself a clinical priority.

Defect location and joint accessibility also shape the decision. Some lesions, particularly those in anatomically constrained positions, may be more reliably reached by one route than the other — a judgement that rests on current imaging and the clinician's intra-procedural assessment rather than on patient preference alone.

The injection pathway carries no published upper age restriction specific to its route, and some evidence suggests the surgical route may place greater reliance on the patient's available regenerative capacity. For patients whose health status makes more intensive procedures inadvisable, the injection route may therefore remain viable where arthroscopic implantation would not.

The determining variables in any given case are anatomical (defect site and joint accessibility), procedural (what the patient's health allows), and clinical (what examination and imaging confirm). Where those three factors point is something a structured assessment can establish — and the answer is unlikely to be the same for every patient.

1. [1] Arthroscopic Assessment of Landmark-Guided Knee Injection Accuracy: A Prospective Observational Study. (2026). https://doi.org/10.1097/PHM.0000000000003057 https://doi.org/10.1097/PHM.0000000000003057
2. [2] Accuracy and Efficacy of Intra-Articular Knee Injections Under Ultrasound versus Landmark Guidance: A Systematic Review. (2025). https://doi.org/10.1097/PHM.0000000000002803 https://doi.org/10.1097/PHM.0000000000002803